6 results about "Alpha protein" patented technology

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

The application belongs to the technical field of protein standard substance value determination, and particularly relates to a TNF-alpha value determination method based on a peptide segment isotope dilution mass spectrometry. The application discloses a TNF-alpha value determination method based on a peptide segment isotope dilution mass spectrometry, which comprises characteristic peptide segment selection (determining ANALLANGVELR and VNLLSAIK as the characteristic peptide segments for quantification according to the amino acid sequence of TNF-alpha), characteristic peptide segment purity determination, characteristic peptide segment mass spectrometry parameter optimization, characteristic peptide segment linear range determination, TNF-alpha protein sample pretreatment, sample enzyme cutting solution mass spectrometry analysis, and characteristic peptide segment content calculation. Finally, the concentration of the target protein in the solution is calculated according to the molecular weights of TNF-alpha and the characteristic peptide segments, and is taken as the quantification result. The TNF-alpha specificity determined by the method is high, and the peptide segments can be traced to the national amino acid standard substance, and finally traced to the SI unit system, so that the accuracy and reliability of the quantification result are ensured.

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

The application discloses application of a chassis strain in heterologous synthesis of a G alpha protein strong inhibitor, and relates to the technical field of biology, B. gladioli Δgbn::attB application of the G alpha protein strong inhibitor FR900359 and YM-254890 in heterologous expression; application of the newly constructed heterologous multi-copy chassis strain in construction of a chassis strain B. gladioli Δgbn::2attB constitutive promoter stnYp driving expression of a FR900359 synthesis gene cluster, after optimization of a fermentation process, FR900359 can be heterologously expressed in a large amount; constitutive promoter stnYp driving expression of a YM-254890 synthesis gene cluster, YM-254890 can be heterologously expressed; in the newly constructed heterologous multi-copy chassis strain B. gladioli Δ gbn::2attB FR900359 and YM-254890 are significantly improved in yield.

Provided are compounds of Formula I, compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).

The present disclosure provides compounds of Formula I for use as inhibitors of alpha-kinase 1 (ALPK1), as well as related compositions and methods.